Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations
Status:
Withdrawn
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
Lucitanib is an oral multi kinase inhibitor designed to block the action of certain molecules
called "angiogenic factors" that may cause tumors to grow. These factors are called vascular
endothelial growth factor (VEGF), platelet derived growth factor receptor (PDGFR) and
fibroblast growth factor (FGF). Lucitanib is experimental and not approved by the FDA for the
treatment of cancer.
The purpose of this study is to look at the effects of lucitanib in cancer patients whose
cancers harbor aberrations in FGFR, VEGFR, PDGFR or other markers predicted to be sensitive
to lucitanib. This study will also look for biomarkers in samples of blood and tumor tissue
to identify patients most likely to respond to lucitanib. Biomarkers are substances such as
genetic material (DNA and RNA) and proteins found in blood and tumor tissue that might show
if a cancer patient will respond or not respond to a drug.